Physician profile
Robert Ansara
NPI 1780869024
$2,559.29
in general payments reported to CMS, 2019-2025
22 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $327 · 2021: $311 · 2022: $232 · 2023: $104 · 2024: $358 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $596.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $430.69 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $383.51 | 2019-2021 | |
| Pfizer INC. | $166.07 | 2019-2024 | |
| Lilly USA, LLC | $123.54 | 2019-2025 | Emgality, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $120.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $112.77 | 2019-2022 | |
| Amarin Pharma, INC. | $108.83 | 2020-2023 | |
| Procept Biorobotics Corporation | $100.23 | 2024 | Aquabeam System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $63.85 | 2019-2025 | Farxiga |
| Abbvie INC. | $48.78 | 2019 | |
| Exact Sciences Corporation | $42.74 | 2023-2025 | Cologuard Collection Kit |
| Vivus LLC | $34.18 | 2024 | Pancreaze |
| Nalpropion Pharmaceuticals LLC | $29.55 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.22 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2019 | |
| Astellas Pharma US INC | $15.43 | 2019 | |
| Gilead Sciences, INC. | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ansara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.